Earlier this month, Colorado BioScience Association (CBSA) engaged on the U.S. Food and Drug Administration’s (FDA) Safety and Landmark Advancements (FDASLA) Act. CBSA and our national partners support the critically important reauthorization of the FDA’s prescription drug, generic drug, biosimilar, and medical device user fee agreements. In a 13-9 vote, the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee approved the FDASLA Act, which reauthorizes most of FDA’s user fee programs and other major provisions. It is important that this legislation ultimately passes for user fees reauthorization. The passed Senate HELP committee legislation included is a manager’s amendment that has a provision requiring the FDA to develop rules for importing drugs from Canada. The plan would allow states to build their own programs then apply for federal approval. It would also require the FDA to legalize personal importation.
The astronauts will use the monitor to track their vital signs on a five-day mission flown by SpaceX. Click here to view original post
A research team supported by the National Institutes of Health has identified characteristics of people with long COVID and those likely to have it. Scientists, using machine learning techniques, analyzed an unprecedented collection of electronic […]
LOUISVILLE, Colo.–(BUSINESS WIRE)–Heidi Hendrix Joins the Sierra Space Executive Leadership Team as Chief People Officer Click here to view original post